The Status of Gene Therapy Development for Retinal Diseases

Opinion
Video

Experts shift to the prospect of gene therapy in treating retinal diseases.

Summary

This segment shifts towards the future of retinal therapies, focusing on gene therapy. David Eichenbaum, MD asks Kenny Fan, MD, MBA about his perspective on gene therapy and the status of ongoing trials. Fan expresses optimism and mentions his enthusiasm for gene therapy, particularly due to the promising clinical and preclinical data. He acknowledges that gene therapy has significant potential, not only for age-related macular degeneration (AMD) and diabetes but also for other hereditary retinal diseases. Fan touches on intravitreal gene therapy and subretinal gene therapy, highlighting their potential benefits. He mentions that the initial results from certain gene therapy trials have been optimistic, and he looks forward to more phase 3 data to further assess the impact of gene therapy on retinal diseases. David Eichenbaum, MD adds to the discussion by distinguishing between gene augmentation for common retinal diseases and gene replacement for inherited retinal diseases. The conversation reflects a sense of optimism and hope for the transformative potential of gene therapy in the treatment of retinal diseases.

This summary was AI-generated and edited for clarity.

Related Videos
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
© 2024 MJH Life Sciences

All rights reserved.